A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

Annals of Neurology

Volumn 68, Issue 4, 2010, Pages 494-502

  Goodman, Andrew D ^a   Brown, Theodore R ^b   Edwards, Keith R ^c   Krupp, Lauren B ^d   Schapiro, Randall T ^e   Cohen, Ron ^f   Marinucci, Lawrence N ^f   Blight, Andrew R ^f  

^a UNIVERSITY OF ROCHESTER   (United States)

^b Evergreen Hospital Medical Center   (United States)

^c Neurological Research Center   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e Minneapolis Clinic of Neurology   (United States)

^f ACORDA THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE DERIVATIVE; DALFAMPRIDINE; PLACEBO; UNCLASSIFIED DRUG; 4 AMINOPYRIDINE; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BALANCE DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FALLING; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PARESTHESIA; PATELLA FRACTURE; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WALKING SPEED; BLOOD; DISABILITY; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; PHYSIOLOGY; WALKING;

4-AMINOPYRIDINE; ADULT; AGED; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; WALKING; YOUNG ADULT;

EID: 78149478174     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22240     Document Type: Article

References (22)

1. Goodman AD, Brown TR, Cohen JA, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732 738.
2. Lechat P, Thesleff S, Bowman WC., Aminopyridines and similarly acting drugs, effects on nerves, muscles and synapses. Oxford, United Kingdom: Pergamon Press, 1982.
3. Judge SI, Bever CT Jr,. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006; 111: 224 259.
4. Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991; 41: 1344 1348.
5. van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992; 32: 123 130.
6. Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44: 1054 1059.
7. Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997; 48: 817 821.
8. Solari A, Uitdehaag B, Giuliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis [review]. Cochrane Database Syst Rev. 2002;(4):CD001330.
9. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007; 13: 357 368.
10. Goodman AD, Brown TR, Cohen JA, et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71: 1134 1141.
11. Hayes KC, Katz MA, Devane JG, et al. Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003; 43: 379 385.
12. Hayes KC, Potter PJ, Hsieh JT, et al. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004; 85: 29 34.
13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121 127.
14. Fischer JS, Jak AJ, Kniker JE, et al. Multiple Sclerosis Functional Composite (MSFC): administration and scoring manual. New York, NY: National Multiple Sclerosis Society, 2001.
15. Medical Research Council (MRC). Aids to the investigation of peripheral nerve injuries. London, United Kingdom: Her Majesty's Stationery Office, 1976.
16. Ashworth B., Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540 542.
17. Hobart JC, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003; 60: 31 36.
18. Kurtzke JF., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444 1452.
19. Cohen RA Kessler HR, Fischer M., The Extended Disability Status Scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis. J Neurol Sci 1993; 115: 132 135.
20. Donovan WH, Halter JA, Graves DE, et al. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000; 38: 7 15.
21. Burton JM, Bell CM, Walker SE, O'Connor PW., 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008; 71: 1833 1834.
22. Eriksson M, Ben-Menachem E, Andersen O., Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002; 8: 495 499.